925908-16-3

Downstream Products

• 1057322-53-8 C₃₁H₄₁FN₄O₂ 
• 1057322-56-1 C₃₁H₄₁FN₄O₂ 
• 925908-00-5 C₂₉H₃₉FN₄O₂ 
• 1039747-73-3 C₃₅H₅₄N₄O₃Si 
• 1039748-22-5 benzyl (R)-3-((R)-1-(1-benzyl-4-(2,5-difluorophenyl)-1H-imidazol-2-yl)-2,2-dimethylpropylamino)-2-(tert-butyldimethylsilyloxy)propylcarbamate 
• 1039748-20-3 benzyl (S)-3-((R)-1-(1-benzyl-4-(2,5-difluorophenyl)-1H-imidazol-2-yl)-2,2-dimethylpropylamino)-2-(tert-butyldimethylsilyloxy)propylcarbamate 
• 1039748-00-9 C₃₂H₃₈N₄O₃ 
• 1039747-49-3 C₂₈H₃₇N₃O₂ 
• 1039747-40-4 C₃₃H₃₆N₄O₃ 
• 1039747-58-4 C₃₂H₃₄N₄O₃ 

Relevant academic research and scientific papers

CYCLIZED DERIVATIVES AS EG-5 INHIBITORS

The present invention relates to new substituted imidazole compounds have the following Formula (I) and to the pharmaceutically acceptable salts, esters, or prodrugs thereof, to compositions of the compounds together with pharmaceutically acceptable carriers, and to uses of the compounds: (I).

Substituted imidazole compounds as KSP inhibitors

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula:

Substituted imidazole derivatives

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: